Medicare Substance Use Disorder Coverage: 2025 Guide

Medicare covers comprehensive substance use disorder (SUD) treatment — including medications for opioid use disorder (methadone, buprenorphine, naltrexone), alcohol use disorder counseling, inpatient and outpatient rehabilitation, and mental health services. Recent policy changes have significantly expanded access, including the 2023 Opioid Treatment Program bundled payment for methadone and the 2024 permanent telehealth prescribing rules that eliminated the in-person visit requirement for buprenorphine.

Substance Use Disorder Coverage at a Glance

Mental Health Parity: SUD Treated the Same as Physical Health

Under the Mental Health Parity and Addiction Equity Act, Medicare covers substance use disorder treatment at the same 20% coinsurance rate as any other medical care. This parity applies across all levels of SUD care — therapy, medication management, intensive outpatient programs, and inpatient treatment. You are never charged a higher cost-sharing rate for SUD treatment than you would be for a medical condition of equivalent severity.

Medicare Advantage plans are also required to comply with mental health parity. If a plan applies more restrictive prior authorization, step therapy, or cost-sharing requirements to SUD services than to comparable medical services, that violates federal parity law.

Free Screenings: Alcohol and Opioid Use Disorder

Medicare covers the following preventive screenings at $0:

• Alcohol misuse screening: Once per year at a primary care visit. Uses validated tools such as the AUDIT-C or single-question screening. If the screen is positive, Medicare covers brief counseling (up to 4 sessions per year) also at $0.
• Opioid use disorder screening: Covered as part of evaluation and management visits; tools like the DAST-10 or ORT may be used.

These free screenings are often the first step toward recognizing and addressing a substance use problem. Primary care providers are encouraged to screen all Medicare patients annually.

Opioid Use Disorder Treatment

Opioid Treatment Programs (OTPs): Methadone Coverage

In 2020, Medicare made a landmark policy change: it began covering methadone for opioid use disorder through certified Opioid Treatment Programs (OTPs). Before 2020, Medicare did not cover methadone for OUD at all — a major gap that left many of the most vulnerable beneficiaries without access to the gold-standard treatment.

The current OTP benefit works as follows:

• Bundled weekly payment: Medicare pays OTPs a bundled weekly rate that covers the methadone itself, counseling services, toxicology testing (drug screens), and care coordination — all in a single payment.
• Cost to patient: 20% coinsurance after the Part B deductible. For patients who cannot afford this, Extra Help (Low Income Subsidy) and Medicaid dual-eligibility can reduce or eliminate cost-sharing.
• Where to receive it: OTPs are federally certified and regulated by SAMHSA. You must receive methadone for OUD at an OTP clinic — it cannot be prescribed at a regular doctor's office.
• How to find an OTP: Use SAMHSA's treatment locator at findtreatment.gov or call SAMHSA's National Helpline at 1-800-662-4357 (free, confidential, 24/7).

Buprenorphine (Suboxone): Office-Based Treatment

Buprenorphine is a partial opioid agonist used for medication-assisted treatment (MAT) of opioid use disorder. Unlike methadone, it can be prescribed in a regular office setting — by your primary care doctor, an addiction medicine specialist, or virtually any licensed prescriber.

Key 2023 policy change: the DEA eliminated the X-waiver requirement for prescribing buprenorphine for OUD. Previously, providers needed to complete an 8-hour training and obtain a special DEA X-waiver. Now, any DEA-licensed provider can prescribe buprenorphine for OUD without additional training or waiver — dramatically expanding the pool of prescribers and reducing barriers to treatment.

Coverage details:

• Oral buprenorphine/naloxone (Suboxone film or tablets): Covered under Part D. Generic versions are available at significantly reduced cost. Subject to the $2,000 annual out-of-pocket cap.
• Sublingual buprenorphine (Subutex): Covered under Part D.
• Extended-release buprenorphine injection (Sublocade): Monthly subcutaneous injection. Covered under Part B if administered by a physician in-office (20% coinsurance), or under Part D if self-administered (subject to OOP cap).

2024 Telehealth Prescribing: Buprenorphine Without an In-Person Visit

In 2024, the DEA finalized rules allowing ongoing buprenorphine prescribing for OUD via telemedicine without requiring a prior in-person visit for patients who are already stable on treatment. This rule was critical for maintaining access for patients in areas with few addiction medicine specialists and those with transportation or mobility barriers. Telehealth OUD visits are covered under Part B at 20% coinsurance.

Naltrexone: Blocking Therapy for OUD

Naltrexone is an opioid antagonist — it blocks opioid receptors, eliminating the euphoric effect of opioids. It is non-addictive and requires complete opioid detoxification before starting.

• Oral naltrexone (generic ReVia): Covered under Part D, Tier 1 generic, typically $0–$10/month.
• Extended-release naltrexone injection (Vivitrol): Monthly intramuscular injection. Covered under Part B at 20% coinsurance when administered by a physician.

Naloxone (Narcan): Life-Saving Rescue Medication

Naloxone rapidly reverses opioid overdose. Since 2023, Medicare Part D plans are required to cover naloxone without prior authorization for beneficiaries who are prescribed opioids at levels that create high overdose risk. This mandatory coverage applies to both intranasal naloxone (Narcan spray) and injectable formulations. If you or a family member takes opioid medications, ask your provider about co-prescribing naloxone — it can save a life in an emergency.

Alcohol Use Disorder Treatment

Free Screening and Brief Counseling

As noted above, alcohol misuse screening is covered at $0 annually. If your screen is positive, Medicare covers up to 4 brief counseling sessions per year at $0 when provided by a primary care physician or other qualified provider in a primary care setting. These brief sessions (typically 15–30 minutes) focus on personalized feedback, goal setting, and strategies for reducing or stopping drinking.

For more extensive counseling needs — beyond 4 sessions, or with a mental health specialist rather than a primary care provider — Part B covers individual and group therapy at 20% coinsurance.

Medications for Alcohol Use Disorder

Three FDA-approved medications for AUD are covered under Part D:

• Naltrexone oral (generic ReVia): Tier 1 generic; reduces cravings and the rewarding effects of alcohol. Non-addictive and generally well-tolerated. Typically $0–$10/month.
• Naltrexone injection (Vivitrol): Monthly injection; Part B at 20% when administered by a physician. Useful for patients with adherence challenges with daily oral medication.
• Acamprosate (Campral): Tier 1–2 generic under Part D; helps maintain abstinence by reducing withdrawal-related dysphoria and anxiety. Taken three times daily.
• Disulfiram (Antabuse): Tier 1 generic under Part D; causes an unpleasant reaction when alcohol is consumed, acting as a deterrent. Requires strong patient motivation and medical supervision.

Levels of SUD Care Covered by Medicare

Outpatient Therapy: Individual and Group

Standard outpatient therapy for SUD — individual sessions with a licensed clinician, or group therapy — is covered under Part B at 20% coinsurance after the deductible. Eligible providers include licensed clinical social workers (LCSWs), psychologists, psychiatrists, psychiatric nurse practitioners, licensed professional counselors (LPCs), and marriage and family therapists (MFTs). There is no annual session limit as long as treatment is medically necessary.

Intensive Outpatient Programs (IOP)

IOPs provide structured treatment more intensive than standard outpatient therapy while allowing patients to live at home. Medicare covers IOPs for SUD under Part B at 20% coinsurance. Requirements:

• At least 3 hours of services per day
• At least 3 days per week
• Services include individual therapy, group therapy, psychoeducation, and relapse prevention
• Must be provided by a Medicare-certified facility

Partial Hospitalization Programs (PHP)

PHPs are hospital-based day programs providing the most intensive level of outpatient SUD care. Typically 6 or more hours per day, 5 days per week. Covered under Part B at 20% coinsurance. PHPs are often used as a step-down from inpatient detox or as an alternative to inpatient care for clinically complex patients who do not require 24-hour supervision.

Inpatient Psychiatric Hospitalization

For acute stabilization, medically managed detoxification, or severe SUD with co-occurring psychiatric crisis, Medicare Part A covers inpatient care:

• Psychiatric unit in a general hospital: No lifetime day limit. Standard Part A cost-sharing: $1,676 deductible per benefit period, then no coinsurance for days 1–60, $419/day for days 61–90, $838/day for lifetime reserve days.
• Freestanding psychiatric hospital: Subject to a 190-day lifetime limit. General hospital units are preferred when multiple inpatient episodes are anticipated.

The Residential Treatment Gap

One of the most significant gaps in Original Medicare's SUD coverage is residential treatment. Residential rehab programs — where patients live at the facility for 30, 60, or 90 days — are generally not covered by Original Medicare unless the facility also qualifies as an inpatient rehabilitation facility (IRF) or meets inpatient hospital criteria. Most standalone residential treatment centers do not meet these criteria.

This means that a 30-day residential program at a typical rehab center would be 100% out of pocket under Original Medicare. For dual-eligible beneficiaries (who have both Medicare and Medicaid), Medicaid often covers residential SUD treatment where Medicare does not — a critical safety net for low-income beneficiaries.

Some Medicare Advantage plans offer enhanced SUD benefits that may include residential treatment coverage. If this level of care is likely to be needed, reviewing MA plan benefits carefully during open enrollment is worthwhile.

Medicare Advantage and SUD Coverage

Medicare Advantage plans must cover all SUD treatments at parity with Original Medicare. Some MA plans offer enhanced SUD benefits beyond what Original Medicare covers, which may include transportation to treatment, peer support services, or coverage for some residential programs. Contact your plan or review your Annual Notice of Change during open enrollment to understand your specific benefits.

Frequently Asked Questions